Fenwick’s Life Sciences Team Named a Law360 “Practice Group of the Year”

Recognizing Fenwick’s resounding impact over the last year, Law360 has named our life sciences team a Practice Group of the Year for 2023. The honor acknowledges Fenwick’s deep expertise and formidable track record successfully guiding the world’s leading biopharma, medical device, diagnostic, and healthcare companies through growth-catalyzing fundraising, pivotal collaborations, industry-shaping mergers, and their highest-stakes disputes.

Law360 highlights Fenwick’s commitment to protecting innovations driving the industry forward, pointing to its long-standing partnership with Novo Nordisk and the team’s recent success in defending its patents for the diabetes drug Ozempic against multiple generic drugmakers. The team is also celebrated for representing DICE Therapeutics in its remarkable $2.4 billion acquisition by Eli Lilly and Company, marking another milestone in Fenwick’s history of facilitating startup-to-sale success stories in biopharma. On the heels of DICE’s acquisition, Fenwick represented Chinook Therapeutics in its $3.5 billion acquisition by Novartis AG, bolstering the Swiss company’s late-stage drug development lineup. Law360 applauds Fenwick's strength in the sector, noting its deep industry experience, advanced technical degrees, and cross-practice collaboration that allow it to keep pace with its clients and the dynamic life sciences industry.

More Fenwick successes that caught Law360’s attention include:

• Raising a combined $1.2 billion for Morphic Therapeutic, Shockwave Medical, and Day One Biopharmaceuticals
• Representing Recludix Pharma’s pivotal collaboration with pharmaceutical giant Sanofi to develop and commercialize first-in-class oral small molecule STAT6 inhibitors
• Conducting IP due diligence for Royalty Pharma before purchasing royalty interests from Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Ferring Pharmaceuticals, and Ascendis Pharma
• Securing a significant pretrial victory for Avalyn Pharmaceuticals in a shareholder earn-out dispute

To read the full profile, click here.

About Fenwick

Fenwick is a leading law firm, purpose-built to guide visionary tech and life sciences companies and their investors through every stage of growth, from startups securing their first round of funding to leading publicly-traded global enterprises. As one of Silicon Valley’s original legal practices, today we have over 500 lawyers, patent agents, engineers and scientists serving clients from seven offices located in innovation hubs across the United States and China. Named 2023 Life Sciences Practice Group of the Year by Law360, we are consistently ranked a Chambers first-tier firm for delivering the deep experience and technical skill that help innovators at the forefront of their industries redefine what’s possible. Visit www.fenwick.com to learn more.